S0931 EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
The purpose of this study is to see whether treatment with a drug called everolimus after surgery for kidney cancer will increase the time without cancer returning.
* Subjects must be 18 years of age or older.
* Subjects must have a confirmed diagnosis of kidney cancer and prior surgery to remove cancer.
* Subject must not have prior anti-cancer treatment expect for a full or partial surgical removal of the affected kidney(s).
* Subject's medical history will be reviewed in detail for study eligibility.
18 - 100
Healthy Volunteers Needed
Duration of Participation
Up to 10 years.
Clinical Trials Information Line: Phone 503-494-1080 or email@example.com